The MIG7 (Migration-Inducing Gene 7) antibody is associated with a protein implicated in cancer metastasis and cell migration. Discovered in the early 2000s, the MIG7 gene encodes a protein that is upregulated in tumor cells, particularly in invasive cancers like breast, colon, and gastric carcinomas. Its expression correlates with enhanced cell motility, angiogenesis, and tumor microenvironment remodeling, making it a potential biomarker for aggressive cancer phenotypes. Mechanistically, MIG7 interacts with pathways involving integrins, growth factors (e.g., VEGF), and extracellular matrix components, facilitating endothelial cell activation and tumor vascularization.
The MIG7 antibody was developed to detect and study this protein's role in cancer progression. It has been utilized in immunohistochemistry, Western blotting, and functional assays to explore MIG7's involvement in metastasis and therapeutic resistance. Research suggests that targeting MIG7 could inhibit tumor spread by disrupting vascular networks or blocking cell invasion signals. Despite its promise, MIG7's precise molecular mechanisms remain partially unresolved, and clinical applications are still in preclinical stages. Ongoing studies aim to validate its utility in diagnostics or as a therapeutic target, leveraging antibody-based strategies to curb metastatic disease.